Literature DB >> 19068012

Severity of depressive symptoms as predictor of impairment of quality of life in chronic migraine: comparison with episodic migraine.

Leonides Canuet1, Ryouhei Ishii, Otman Fernandez-Concepcion, Masao Iwase, Masatoshi Takeda.   

Abstract

To identify predictors of quality of life (QoL) in episodic migraine (EM) and chronic migraine (CM), 116 migraineurs were evaluated using the Headache Needs Assessment (HANA). QoL was significantly more impaired in patients with CM. Disability was a predictor of QoL in both EM and CM. Severity of depressive symptoms emerged as a predictor of QoL in CM. QoL was also poorer in women and in those with greater headache intensity and nausea associated with headache in the total sample. The present findings suggest a specific role for depressive symptoms in impaired QoL in CM sufferers.

Entities:  

Mesh:

Year:  2008        PMID: 19068012     DOI: 10.1111/j.1440-1819.2008.01867.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  6 in total

1.  The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study.

Authors:  Sun-Young Kim; Sung-Pa Park
Journal:  J Headache Pain       Date:  2014-10-02       Impact factor: 7.277

2.  Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain.

Authors:  Domingo Palacios-Ceña; Beatriz Neira-Martín; Lorenzo Silva-Hernández; Diego Mayo-Canalejo; Lidiane Lima Florencio; César Fernández-de-Las-Peñas; Héctor García-Moreno; David García-Azorín; María Luz Cuadrado
Journal:  BMJ Open       Date:  2017-08-21       Impact factor: 2.692

3.  Migraine Outcome Should Not Be Used to Determine Diagnosis, Severity, and Therapy: Moving Towards a Multiparametric Definition of Chronicity.

Authors:  Alberto Raggi; Matilde Leonardi; Simona Sacco; Paolo Martelletti
Journal:  Pain Ther       Date:  2022-03-29

4.  A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States.

Authors:  Lynda J Krasenbaum; Vasantha L Pedarla; Stephen F Thompson; Krishna Tangirala; Joshua M Cohen; Maurice T Driessen
Journal:  J Headache Pain       Date:  2022-05-04       Impact factor: 8.588

5.  Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.

Authors:  Richard B Lipton; Joshua M Cohen; Maja Galic; Michael J Seminerio; Paul P Yeung; Ernesto Aycardi; Marcelo E Bigal; Kristen Bibeau; Dawn C Buse
Journal:  Headache       Date:  2021-04       Impact factor: 5.887

6.  Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.

Authors:  Peter McAllister; David Kudrow; Roger Cady; Joe Hirman; Anders Ettrup
Journal:  Cephalalgia       Date:  2022-03-25       Impact factor: 6.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.